The deal would give GSK the rights to develop the drug for HRD-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...

Pfizer has licensed global rights to 3SBio’s cancer drug SSGJ-707 for USD 1.25 billion upfront, in what may be the largest single-drug deal in China’s biotech sector. It will pay an additional USD 150 ...

The star of GSK’s Hengrui partnership is the COPD candidate HRS-9821, which will complement the pharma’s respiratory pipeline ...